Compare Natera Inc. Common Stock (NTRA) vs Veeva Systems (VEEV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Veeva Systems — how do they compare? Natera Inc. Common Stock trades at $394.6 (market cap $57.03B), while Veeva Systems trades at $296 (market cap $48.84B). The key difference: Natera Inc. Common Stock is the larger of the two by market cap, and Veeva Systems is more actively traded (2,253,175 versus 1,131,157). Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Veeva Systems for 6 Days on average.
| NTRA | VEEV | |
|---|---|---|
Market Cap | $57.03B | $48.84B |
Volume | 1,131,157 | 2,253,175 |
Sector | Health | Technology |
52-Week High | $425.64 | $301.63 |
52-Week Low | $179.42 | $151.43 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $56.18B | $41.75B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Veeva Systems (VEEV) trades at $301.63, up 1.95% with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with 74.96% gross margins and consistent earnings beats, while expanding partnerships with IQVIA and Servier enhance growth prospects. Recent news highlights AI innovations and increasing adoption among biotech firms, supporting positive sentiment.
Outlook remains favorable with analyst consensus at Buy (67% rating) and $290.50 price target, though valuation multiples appear elevated. Key risks include market saturation concerns and potential volatility from RSI overbought signals. The stock's proximity to 52-week highs suggests continued investor confidence in Veeva's life sciences software leadership.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Veeva Systems
Veeva Systems provides cloud software, data, and services for the life sciences industry. Its applications support functions across clinical research, regulatory operations, quality, safety, and commercial teams.
Read more on VEEV →
